SETD7 and breast cancer: Finally, to compare a global hypomethylating strategy to other strategies used to target specific components of the epigenetic machinery in cancer cells, we evaluated the effect of combining IR with either 5-Aza-dC, a DNA-hypomethylating agent, or (R)-PFI-2, a potent and selective inhibitor of SET9.20 As shown in Figure 4d, these combined treatments were unable to induce apoptosis in these BC cells.